Core Viewpoint - Gannee Pharmaceutical has signed significant contracts with Brazil's Ministry of Health and BIOMM S.A., marking a major step in its international expansion and commitment to the Brazilian insulin market [1][2][3] Group 1: Contract Details - The company has entered into a "Technology Transfer and Supply Agreement" and a "Supply Framework Agreement" with BIOMM, with the total contract value expected to be no less than RMB 3 billion over a 10-year period [1][3] - The agreements are part of Brazil's Production Development Partnership (PDP) initiative, aimed at enhancing local drug production through technology transfer from multinational pharmaceutical companies [1][2] Group 2: Strategic Importance - Gannee Pharmaceutical is the first Chinese pharmaceutical company to be included in Brazil's PDP project, indicating a new phase in Sino-Brazilian biopharmaceutical cooperation [2] - The contracts will enable Gannee to supply insulin products to Brazil, establishing a stable supply chain for the Brazilian insulin market over the next decade [2][3] Group 3: International Expansion - The company has been actively pursuing international market expansion, responding to the "Belt and Road" initiative, and has engaged in collaborations in over 20 countries, including Pakistan, Kazakhstan, Argentina, and Malaysia [3] - In the first half of 2025, Gannee's international sales revenue reached RMB 219 million, a year-on-year increase of 74.68%, with multiple insulin products approved for registration in Malaysia and Pakistan [3]

Group 1 - The core viewpoint of the news is that Ganli Pharmaceutical has signed a technology transfer and supply agreement with Brazil's Ministry of Health's public laboratory Funda o Oswaldo Cruz-Bio-Manguinhos (FZ) and Brazilian biopharmaceutical company BIOMM S.A., with a contract amount expected to be no less than RMB 30 billion over a 10-year period [1][2][3] Group 2 - The collaboration is part of Brazil's Production Development Partnership (PDP) program, aimed at promoting local drug production through technology transfer from multinational pharmaceutical companies, ensuring a stable supply of essential medicines in Brazil [2] - Ganli Pharmaceutical is the first Chinese pharmaceutical company to enter the PDP program in Brazil, marking a new phase in Sino-Brazilian biopharmaceutical cooperation [2][3] - The approved proposal involves Ganli Pharmaceutical transferring technology related to insulin to FZ and supplying raw materials and injectable insulin to BIOMM, which will then transfer filling processes to FZ [3] - The agreement is expected to significantly enhance the stability of insulin supply in Brazil's public healthcare system over the next decade, addressing long-term medication accessibility issues for diabetes patients [3] - The independent commercial cooperation agreement with BIOMM covers raw materials, injectable insulin, and insulin pens, with a projected cumulative order amount of no less than RMB 30 billion over ten years [3] - Successful implementation of this agreement is anticipated to positively impact Ganli Pharmaceutical's operating performance in 2025 and beyond, enhancing overall profitability [3]

24 September 2025 | 12:32PM CST Gan & Lee Pharmaceuticals Co. (603087.SS): New agreement under Brazil's PDP, total value to exceed Rmb3bn; TP up to Rmb77; Buy Gan & Lee announced that it has signed a technology transfer and supply agreement with Brazil's government research institution Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and local pharmaceutical company BIOMM S.A., as well as a supply framework agreement with BIOMM. The total contract value is expected to exceed Rmb3bn per the company, with a term of ...

Market Overview - On September 24, the biopharmaceutical sector rose by 0.09% compared to the previous trading day, with Ganli Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Ganli Pharmaceutical (603087) closed at 79.34, with a significant increase of 10.00% and a trading volume of 343,300 shares, resulting in a transaction value of 2.696 billion yuan [1] - Other notable performers included: - Sanofi (688336) at 55.98, up 5.11% with a transaction value of 431 million yuan [1] - Aidi Pharmaceutical (688488) at 15.26, up 4.88% with a transaction value of 174 million yuan [1] - Nuoviz (688105) at 22.65, up 4.47% with a transaction value of 91.03 million yuan [1] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 86.36 million yuan from institutional investors, while retail investors experienced a net outflow of 69.34 million yuan [2] - The capital flow for individual stocks showed that Ganli Pharmaceutical had a net inflow of 14.4 million yuan from institutional investors, but a net outflow of 85.14 million yuan from retail investors [3] - Changchun High-tech (000661) had a net inflow of 43.56 million yuan from institutional investors, while retail investors faced a net outflow of 88.37 million yuan [3]

Group 1 - The stock price of Ganli Pharmaceutical (SH:603087) reached its daily limit, closing at 79.34 yuan, with an increase of 10.00% [1] - The total market capitalization of Ganli Pharmaceutical is 47.408 billion yuan [1]

Group 1 - The company has signed a Technology Transfer and Supply Agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM for the Brazil Production Development Partnership (PDP) project, with a total contract value expected to be no less than RMB 300,000 million (including tax) [1] - The PDP project aims to strengthen the public health system in Brazil and ensure a stable supply of essential medicines by transferring advanced product technology from multinational pharmaceutical companies to local production [1][2] - The company's proposal for the PDP project has been approved by the Brazilian government, establishing it as the only approved plan for the project [2] Group 2 - The contract specifies that the company will transfer the technology for insulin glargine to FZ and supply insulin glargine injection and raw materials to BIOMM, which will in turn transfer the filling technology to FZ [2] - FZ, as the technology recipient and final purchaser, commits to purchasing the agreed quantities and prices from BIOMM over the next 10 years [2]

Market Overview - The Shanghai Composite Index closed at 3848.69 points, above the five-day moving average, with an increase of 0.70% [1] - The total trading volume of A-shares reached 188.67 billion yuan [1] Stock Performance - A total of 1219 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - Stocks with the highest deviation rates include: - Henghe Co., Ltd. with a deviation rate of 20.94% and a daily increase of 29.98% [1] - Shangwei New Materials with a deviation rate of 15.29% and a daily increase of 20.00% [1] - Xingfu Electronics with a deviation rate of 14.88% and a daily increase of 19.99% [1] - Other stocks with smaller deviation rates that just crossed the five-day moving average include Aotai Biological, Yongjin Co., Ltd., and Fuyuan Pharmaceutical [1] Detailed Stock Data - The following table summarizes key stocks that have broken through the five-day moving average: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Five-Day MA (yuan) | Latest Price (yuan) | Deviation Rate (%) | | --- | --- | --- | --- | --- | --- | --- | | 832145 | Henghe Co., Ltd. | 29.98 | 16.33 | 26.71 | 32.30 | 20.94 | | 688585 | Shangwei New Materials | 20.00 | 4.32 | 95.48 | 110.08 | 15.29 | | 688545 | Xingfu Electronics | 19.99 | 33.75 | 34.23 | 39.32 | 14.88 | | 300421 | Lixing Co., Ltd. | 19.24 | 28.95 | 16.37 | 18.72 | 14.36 | | 300379 | *ST Dongtong | 15.32 | 29.26 | 2.40 | 2.71 | 12.73 | | 300854 | Zhonglan Environmental Protection | 19.99 | 14.32 | 20.87 | 23.17 | 11.04 [1]

Market Overview - The Shanghai Composite Index is at 3820.93 points, slightly below the five-day moving average, with a change of -0.02% [1] - The total trading volume of A-shares today is 10109.58 billion yuan [1] Stocks Breaking the Five-Day Moving Average - A total of 582 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - Henghe Co., Ltd. with a deviation rate of 20.94% and a daily increase of 29.98% [1] - Shangwei New Materials with a deviation rate of 15.29% and a daily increase of 20.00% [1] - *ST Dongtong with a deviation rate of 12.08% and a daily increase of 14.47% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the five-day moving average include: - Hualing Agricultural Industry with a deviation rate of 7.86% and a daily increase of 9.93% [1] - Ganli Pharmaceutical with a deviation rate of 7.59% and a daily increase of 10.00% [1] - Tongfu Microelectronics with a deviation rate of 7.04% and a daily increase of 10.00% [1]

Core Points - The Shanghai Composite Index closed at 3845.91 points, above the five-day moving average, with a gain of 0.63% [1] - The total trading volume of A-shares reached 1,420.282 billion yuan [1] - A total of 1,040 A-shares have prices that surpassed the five-day moving average, indicating positive market sentiment [1] Summary of Stocks with Significant Deviation from the Five-Day Moving Average - Henghe Co., Ltd. (证券代码: 832145) saw a price increase of 29.98% with a deviation rate of 20.94% [2] - Shangwei New Materials (证券代码: 688585) experienced a 20.00% increase and a deviation rate of 15.29% [2] - Xingfu Electronics (证券代码: 688545) rose by 19.99% with a deviation rate of 14.88% [2] - Other notable stocks include Zhongwei Semiconductor (证券代码: 688380) with a 15.64% increase and a deviation rate of 11.28% [2] - ST Dongtong (证券代码: 300379) increased by 13.19% with a deviation rate of 11.11% [2] - Qidi Environment (证券代码: 000826) rose by 10.18% with a deviation rate of 7.98% [2] - He Yuan Gas (证券代码: 002971) increased by 10.01% with a deviation rate of 7.92% [2] - Yangyuan Beverage (证券代码: 603156) saw a 9.98% increase with a deviation rate of 7.83% [2]

Group 1 - Tianan New Materials plans to reduce its shareholding by no more than 0.22%, totaling up to 667,000 shares, due to personal funding needs [1] - Fulongma's urban service robots are still in the initial expansion phase, primarily used for internal sanitation projects, with low external sales [1][2] - Shennma Co. intends to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 14.97 yuan per share, aiming to reduce registered capital [3] - Poly Developments plans to issue corporate bonds not exceeding 15 billion yuan, with proceeds intended for debt repayment, working capital, project construction, and acquisitions [4] - Ganli Pharmaceutical signed a significant contract for the Brazil PDP project, expected to exceed 3 billion yuan, involving the supply of insulin raw materials and injection devices over ten years [5] - Jingce Electronics' actual controller plans to transfer 5.02% of the company's shares at a price of 60.24 yuan per share [6] - ST Xingnong's shareholder intends to reduce holdings by up to 3% of the company's shares, totaling approximately 811,350 shares [7] - Zhejiang Lino plans to reduce its shareholding by up to 3.25%, involving multiple stakeholders [8] - Chuling Information holds a minor indirect stake of 0.0229% in Moer Thread through its investment in Zhongyi Fund [9] - Jinpu Titanium Industry has decided to terminate a major asset restructuring due to market uncertainties [10] - ST Lian Stone's stock will be subject to delisting risk warning following its bankruptcy reorganization application [13] - Aerospace Technology appointed Zhong Min as the new general manager [14] - Aerospace Technology's subsidiary plans to publicly transfer 50% of its intangible assets related to a drilling system [14] - Nanxing Co. plans to reduce its shareholding by up to 3.03%, with multiple executives also planning to reduce their stakes [15] - Jiangsu Guotai's actual controller is planning a non-compensatory transfer of state-owned equity, changing the actual controller to a state asset management center [16] - Yashida Optoelectronics plans to reduce its shareholding by up to 400,000 shares due to personal funding needs [17] - Yuntuo Holdings successfully acquired a 49% stake in Shenglong Mining, with plans to provide financial support for its operations [18] - Ice Wheel Environment's directors and executives plan to reduce their holdings by no more than 22,750 shares [19] - Ruijia New Materials' actual controller will change following a non-compensatory transfer of state-owned equity [20] - Zhejiang Xiantong plans to establish a joint venture with Haohai Starry Sky, investing 40 million yuan for a 10% stake [21] - Inspur Software received approval from the CSRC for a stock issuance to specific investors [22] - Chuangye Huikang's shareholder plans to reduce holdings by up to 37,038,000 shares [23]